文献速递认知障碍与痴呆

Lanabecestat治疗早期及轻度阿尔茨海默病的疗效与安全性:AMARANTH与DAYBREAK-ALZ随机临床试验

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
PubMed 文献 · JAMA Neurol · 2020-01-01

两项随机、双盲、安慰剂对照试验评估Lanabecestat(BACE1抑制剂)对早期AD及轻度AD痴呆的疗效。AMARANTH(2218例)和DAYBREAK-ALZ(1722例)均因无效分析提前终止,未发现一致的可重复的剂量相关疗效,精神不良事件、体重减轻及发色改变在Lanabecestat组更常见。

要点

  • Lanabecestat未减缓早期AD或轻度AD痴呆患者的认知或功能下降。
  • 两项试验均因无效分析提前终止,无一致可重复的剂量相关疗效。
  • Lanabecestat组精神不良事件、体重减轻及发色改变发生率高于安慰剂组。

核心结论

  • Lanabecestat治疗耐受性良好,但未减缓认知或功能衰退。

研究设计与样本

  • AMARANTH为随机、安慰剂对照、双盲2/3期试验,持续104周,在15个国家或地区的257个中心进行,筛查6871例,随机2218例(32.3%),完成539例。
  • DAYBREAK-ALZ为随机、安慰剂对照、双盲3期试验,持续78周,在18个国家或地区的251个中心进行,筛查5706例,随机1722例(30.2%),完成76例。
  • 纳入55至85岁符合美国国家衰老研究所-阿尔茨海默病协会早期AD或轻度AD痴呆标准且淀粉样蛋白确认的男性与女性。

主要发现

  • AMARANTH患者平均(SD)年龄71.3(7.1)岁,女性1177/2218(53.1%)。
  • DAYBREAK-ALZ患者平均(SD)年龄72.3(7.0)岁,女性1023/1722(59.4%)。
  • 两项研究均因无效分析提前终止,主要或次要疗效指标均无一致、可重复的剂量相关发现。
  • Lanabecestat组报告精神不良事件、体重减轻及发色改变的患者百分比高于安慰剂组。

关键数值与推荐

  • 主要结局指标为13项阿尔茨海默病评估量表-认知子量表(ADAS-cog)评分自基线的变化。
  • 次要结局包括阿尔茨海默病协作研究-工具性日常生活活动量表、临床痴呆评定量表、功能活动问卷、简易精神状态检查及神经精神问卷。
  • 患者按1:1:1随机接受每日一次口服Lanabecestat 20 mg、50 mg或安慰剂。

临床怎么用

  • Lanabecestat不应用于减缓早期AD或轻度AD痴呆的疾病进展。
  • 使用BACE1抑制剂时需监测精神不良事件、体重减轻及发色改变。

局限性

  • 两项试验均因无效分析提前终止,完成率低(AMARANTH完成539例,DAYBREAK-ALZ完成76例)。
  • 排除了不稳定医疗状况或用药、显著脑血管病理、白癜风病史和/或当前炎症后色素减退证据的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living. Current treatments provide only minor symptomatic improvements with limited benefit duration. Lanabecestat, a brain-permeable inhibitor of human beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1/β-secretase), was developed to modify the clinical course of AD by slowing disease progression. OBJECTIVE: To assess whether lanabecestat slows the progression of AD compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia. DESIGN, SETTING, AND PARTICIPANTS: AMARANTH (first patient visit on September 30, 2014; last patient visit on October 4, 2018) and DAYBREAK-ALZ (first patient visit on July 1, 2016; last patient visit on September 28, 2018) were randomized, placebo-controlled, phase 2/3 and phase 3 clinical trials lasting 104 weeks and 78 weeks, respectively. AMARANTH and DAYBREAK-ALZ were multicenter, global, double-blind studies conducted at 257 and 251 centers, respectively, located in 15 and 18 countries or territories, respectively. A population-based sample of men and women aged 55 to 85 years who met National Institute on Aging-Alzheimer's Association criteria for early AD or mild AD dementia was screened using cognitive assessments, and the presence of amyloid was confirmed. Patients were excluded for unstable medical conditions or medication use, significant cerebrovascular pathologic findings, or a history of vitiligo and/or current evidence of postinflammatory hypopigmentation. AMARANTH screened 6871 patients; 2218 (32.3%) were randomized, and 539 patients completed the study. DAYBREAK-ALZ screened 5706 patients; 1722 (30.2%) were randomized, and 76 patients completed the study. INTERVENTIONS: Patients were randomized (1:1:1) to once-daily oral doses of lanabecestat (20 mg), lanabecestat (50 mg), or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome measure was change from baseline on the 13-item Alzheimer Disease Assessment Scale-cognitive subscale. Secondary outcomes included Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory, Clinical Dementia Rating, Functional Activities Questionnaire, Mini-Mental State Examination, and Neuropsychiatric Inventory. Efficacy analyses were conducted on the intent-to-treat population. RESULTS: Among 2218 AMARANTH patients, the mean (SD) age was 71.3 (7.1) years, and 1177 of 2218 (53.1%) were women. Among 1722 DAYBREAK-ALZ patients, the mean (SD) age was 72.3 (7.0) years, and 1023 of 1722 (59.4%) were women. Both studies were terminated early after futility analysis. There were no consistent, reproducible dose-related findings on primary or secondary efficacy measures. Psychiatric adverse events, weight loss, and hair color changes were reported in a higher percentage of patients receiving lanabecestat than placebo. CONCLUSIONS AND RELEVANCE: Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT02245737 and NCT02783573.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials. JAMA Neurol. 2020. PMID: 31764959. doi:10.1001/jamaneurol.2019.3988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。